With new drugs coming out each month and many becoming best sellers we wonder which of these will start to implicate the manufacturer for lack of warnings for a medical condition. We already know that Xarelto has lawsuits for excessive bleeding and Yaz just reached a settlement for causing blood clots and related medical conditions.
According to Medscape Medical news the cholesterol-lowering drug rosuvastatin (Crestor, AstraZeneca) has been the most prescribed branded drug in the United States, and the arthritis drug adalimumab (Humira, Abbott Laboratories) was the best-selling branded drug, according to the latest data from research firm IMS Health.
Rosuvastatin had about 21 million prescriptions, followed by asthma medication fluticasone propionate/salmeterol (Advair Diskus, GlaxoSmithKline), at about 13.6 million prescriptions; the proton pump inhibitor esomeprazole (Nexium, AstraZeneca), at about 13.2 million prescriptions; the insulin glargine injection Lantus Solostar (sanofi-aventis), at about 11.2 million; and the attention-deficit drug lisdexamfetamine dimesylate (Vyvanse, Shire), at about 10.6 million.
Rounding out the top 10 most prescribed drugs for the period (in order) were the antiepileptic drug pregabalin (Lyrica, Pfizer), the chronic obstructive pulmonary disease medication tiotropium bromide (Spiriva Handihaler, Boehringer Ingelheim Pharmaceuticals), the diabetes drug sitagliptin (Januvia, Merck), the asthma/chronic obstructive pulmonary disease drug budesonide/formoterol (Symbicort, AstraZeneca), and the antipsychotic medication aripiprazole (Abilify, Otsuka Pharmaceutical).
The top seller, arthritis drug adalimumab (Humira, Abbott Laboratories), had sales of about $8.6 billion, followed by the antipsychotic aripiprazole (Abilify, Otsuka Pharmaceutical), at $7.2 billion; the arthritis drug etanercept (Enbrel, Amgen), at roughly $6.1 billion; the cholesterol drug rosuvastatin (Crestor, AstraZeneca), at just under $6.1 billion; and the insulin glargine injection Lantus Solostar (sanofi-aventis), at around $5 billion.
The remaining top 10 drugs in sales were the hepatitis C drug sofosbuvir (Sovaldi, Gilead Sciences), at $4.9 billion; the asthma drug fluticasone propionate/salmeterol (Advair Diskus, GlaxoSmithKline), at $4.8 billion; the proton pump inhibitor esomeprazole (Nexium, AstraZeneca), at $4.7 billion; the diabetes drug sitagliptin (Januvia, Merck), at $3.8 billion; and the antiepileptic pregabalin (Lyrica, Pfizer), at $3.4 billion.
Top 100 Brands by Sales
Product Sales, $
Abilify $7,238,451,779 Current lawsuits by Abilify lawyers
Lantus Solostar $5,023,092,599
Advair Diskus $4,769,250,836
Januvia $3,792,531,657 Current lawsuits pending
Spiriva Handihaler $3,388,442,306
Xarelto $2,460,606,162 Current lawsuits pending
Novolog Flexpen $2,212,204,664
Humalog Kwikpen $1,588,639,456
Viagra $1,375,305,952 Recent lawsuits for Melanoma
Seroquel XR $1,359,121,073
Androgel $1,182,514,119 Current lawsuits pending
Namenda XR $857,157,299
Pradaxa $850,313,699 Current lawsuits pending- Pradaxa lawyers
Nuvaring $690,996,076 Nuvaring lawyers
Mirena $603,038,710 Lawsuits and MDL- Mirena IUD Lawyers
Premarin Vaginal $397,570,841
Epipen Jr 2-Pak $389,528,868
Breo Ellipta $140,349,328
Quillivant XR $107,092,690
Anoro Ellipta $64,460,164
Yaz-28 $49,432,035 Yas lawyers- settlement just announced
Ambien CR $45,955,805
Boniva $16,056,457 Boniva lawyers filing lawsuits
Reclast $11,208,523 Lawsuits being filed
Botox Cosmetic $952,021
Victoza Unsp N-N
Grand total $112,494,804,575
article courtesy of Medscape Medical News © 2015 WebMD, LLC